SCHEMBL3763986

SCHEMBL3763986

CS(=O)(=O)Nc1cccc(-c2cnc3[nH]cc(-c4ccc(CC(=O)O)cc4)c3c2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 3/20 0.65
TNIK Q9UKE5 6/20 0.63
PIK3CA P42336 2/20 0.61
DYRK1A Q13627 2/20 0.60
CLK1 P49759 1/20 0.60
DYRK2 Q92630 1/20 0.60
DYRK1B Q9Y463 1/20 0.60
CAMKK2 Q96RR4 2/20 0.58
NTRK1 P04629 4/20 0.55
KIT P10721 1/20 0.54
AXL P30530 2/20 0.54
NEK1 Q96PY6 1/20 0.53
IGF1R P08069 1/20 0.53
RIPK1 Q13546 1/20 0.53
CDC7 O00311 1/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
MAPK13 O15264 1/20 0.53
PDPK1 O15530 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769360 0.91 TNIK (0.61) SGK1TNIKPIK3CADYRK1ACLK1
SCHEMBL3771011 0.90 CLK1 (0.74) SGK1TNIKDYRK1ACLK1DYRK2
SCHEMBL3807981 0.88 SGK1 (0.67) SGK1TNIKPIK3CADYRK1ACLK1
SCHEMBL3765020 0.87 CAMKK2 (0.75) SGK1TNIKPIK3CADYRK1ACLK1
SCHEMBL3763949 0.87 CAMKK2 (0.77) SGK1TNIKDYRK1ACAMKK2NTRK1
SCHEMBL3761616 0.84 SGK1 (0.73) SGK1TNIKPIK3CADYRK1ACLK1
SCHEMBL3765757 0.83 AXL (0.72) SGK1TNIKPIK3CADYRK1ACLK1
SCHEMBL3765153 0.82 NTRK1 (0.73) SGK1TNIKPIK3CADYRK1ACAMKK2
SCHEMBL3759550 0.82 SGK1 (0.71) SGK1DYRK1ACAMKK2NTRK1KIT
SCHEMBL3771136 0.82 TNIK (0.64) SGK1TNIKPIK3CADYRK1ACLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US claimed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO claimed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US claimed
EP-1828180-A1 1H-PYRROLO[2,3-BETA]PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2007-09-05 EP claimed
WO-2006063167-A1 1H-PYRROLO[2,3-B]PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2006-06-15 WO claimed
WO-2021006707-A1 USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES 한양대학교 산학협력단 2021-01-14 WO disclosed
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US disclosed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO disclosed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes SGK1, SGK2, SGK3 SGK1 1/4885TNIK 212/4885PIK3CA 335/4885
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines SGK1, SGK2, SGK3 SGK1 1/4885TNIK 213/4885PIK3CA 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.